Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
December 11, 2018 12:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
November 30, 2018 08:55 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
November 29, 2018 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
November 08, 2018 16:30 ET
|
Keryx Biopharmaceuticals, Inc.
Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017Approximately...
Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018
November 06, 2018 16:30 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics
October 30, 2018 17:31 ET
|
Keryx Biopharmaceuticals, Inc.
Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders to vote “FOR” the Merger Proposals Keryx Special Meeting of Stockholders Scheduled for December 11, 2018 BOSTON, Oct. ...
Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference
October 01, 2018 09:16 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results
August 08, 2018 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
Second quarter 2018 total revenues of $25.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $24.1 million; a 71 percent increase compared to the second quarter of...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
August 02, 2018 16:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st
June 20, 2018 09:21 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...